Clinical Trial Update: A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation [Phase 2]

View source ↗

Summary

Phase 2 study of Venglustat (GZ/SAR402671) in Parkinson's disease patients with a GBA mutation was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Venglustat (venglustat)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Parkinson's Disease | Phase 2 | Status: TERMINATED | Results posted: 2022-02-28